IMMUNOMEDICS, INC. : EPRATUZUMAB AND RITUXIMAB PRODUCE HIGH ... 4-traders (press release) based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that the combination of epratuzumab and rituximab, as a front-line therapy of patients with newly diagnosed follicular lymphoma (FL), produced a ... |
